Teplizumab
Based on 1 publication(s) in Google Scholar
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.73%
- CAS No.: 876387-05-2
- Masse moléculaire:150 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Teplizumab
More
Activité biologique
Human IgG1 (L234A/L235A) kappa
Human
CD3E
Teplizumab (10 ng/mL-10 μg/mL, 5 days) induces human CD8+ T-cell proliferation[3].
Teplizumab (6 days) increases the expression of CD25 and intracellular CTLA4 on CD8+ cells (freshly isolated PBMCs)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human PBMCs
-
Concentration:10 ng/mL, 100 ng/mL, 1 μg/mL, 10 μg/mL.
-
Incubation Time:5 days
-
Result:Induced cell proliferation (measured by incorporation of [3H]thymidine in a 5-day assay.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID IL2γc-/- (NSG) mice (a tolergenic humanized mouse model)[1]
-
Dosage:0.24 mg/kg, 5 μg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Decreased CD4:CD8 ratio in the peripheral blood from 2.03 to 1.01, p < 0.05.
Decreased circulating hCD4 cells in the peripheral blood.
Decreased in the proportion of T cells in the bone marrow and lung.
Increased in the total number of human CD45+ cells infiltrating the lamina propria of the small intestine.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized Human CD3D&CD3E can bind Teplizumab. The EC50 for this effect is 102.5 ng/mL. -
Flow cytometric analysis of 106 Jurkat cells with Teplizumab (HY-P99222, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 876387-05-2
-
Appearance Liquid
-
Masse moléculaire 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Teplizumab]
-
Synonyms
MGA-031; PRV-031
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureté et documentation
-
Fiche technique (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Kevan C Herold, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 Aug 15;381(7):603-613. [Content Brief]
[2]. Frank Waldron-Lynch, et al. I Analysis of FcR non-binding anti-CD3 mAb in humanized mice identifies novel human gut tropic cells with regulatory function that are found in patients. Sci Transl Med. 2012 Jan 25;4(118):118ra12. [Content Brief]
[3]. Brygida Bisikirska, et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005 Oct;115(10):2904-13. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Teplizumab Related Classifications
HY-P99222 Related Classifications
Powered by Bioz